74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Arvinas Inc
Closed
SectorHealthcare
6.56 4.63
Overview
Share price change
24h
Min
6.33
Max
6.72
Income | 128M 83M |
|---|---|
Sales | 130M 189M |
EPS | 1.14 |
Profit margin | 43.909 |
Employees | 430 |
EBITDA | 129M 73M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +126.87% upside |
Next Earnings | 29 Oct 2025 |
|---|
Market Cap | -84M 550M |
|---|---|
Previous open | 1.93 |
Previous close | 6.56 |
News Sentiment
By Acuity
60%
40%
322 / 374 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Arvinas Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Arvinas Inc Forecast
Price Target
By TipRanks
126.87% upside
12 Months Forecast
Average 14.27 USD 126.87%
High 21 USD
Low 6 USD
Based on 14 Wall Street analysts offering 12 month price targets forArvinas Inc - Dist in the last 3 months.
Sentiment
By Acuity
322 / 374 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
